Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 5:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 126 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: amlodipine (drug) Clear all
Completed Phase 2 Interventional Results available

Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

NCT05103332
View directory record Official record
Conditions
Hypertension
Interventions
Indapamide, Amlodipine, Olmesartan, Placebo, Zilebesiran
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
74
States / cities
Mesa, Arizona • Tempe, Arizona • Bell Gardens, California + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Sep 28, 2026, 5:12 PM EDT
Withdrawn Phase 4 Interventional

Regression of Fatty Heart by Valsartan Therapy

NCT00745953
View directory record Official record
Conditions
Metabolic Syndrome, Lipotoxicity
Interventions
Valsartan, Hydrochlorothiazide
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Sep 28, 2026, 5:12 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome

NCT01271374
View directory record Official record
Conditions
Hypertension
Interventions
amlodipine and olmesartan, losartan and HCTZ
Drug
Lead sponsor
InVasc Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tucker, Georgia
Source: ClinicalTrials.gov public record
Updated May 4, 2011 · Synced Sep 28, 2026, 5:12 PM EDT
Recruiting Phase 4 Interventional

Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study

NCT04191681
View directory record Official record
Conditions
Stage D Heart Failure
Interventions
Sacubitril-Valsartan, Usual care (standard-of-care) arm
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Sep 28, 2026, 5:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension

NCT01996449
View directory record Official record
Conditions
Hypertension
Interventions
Eplerenone, Amlodipine, Microneurography, Rhythmic handgrip exercise, Sustained hand grip, Forearm blood flow, Arm cycling exercise, Cold Pressor test
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Sep 28, 2026, 5:12 PM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 28, 2026, 5:12 PM EDT
Completed Phase 4 Interventional

Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension

NCT00139555
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy
Interventions
amlodipine/benazepril
Drug
Lead sponsor
Novartis
Industry
Eligibility
55 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 28, 2026, 5:12 PM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Nebivolol Versus Metoprolol in Hypertensive Subject Taking Amlodipine

NCT03635125
View directory record Official record
Conditions
JNC 7 Stage 1 or 2 Hypertension
Interventions
Nebivolol I, Nebivolol II, Baseline Washout Phase
Drug · Other
Lead sponsor
Trinity Hypertension & Metabolic Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Carrollton, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Sep 28, 2026, 5:12 PM EDT
Completed Phase 2Phase 3 Interventional

Risk Reduction for Alzheimer's Disease

NCT02913664
View directory record Official record
Conditions
Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Alzheimer's Disease
Interventions
Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine), Aerobic Exercise Training, Usual Care, Stretching Exercise
Drug · Behavioral · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
60 Years to 85 Years
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Kansas City, Kansas • Baton Rouge, Louisiana • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Sep 28, 2026, 5:12 PM EDT
Active, not recruiting Phase 4 Interventional

MR Antagonist and LSD1

NCT04840342
View directory record Official record
Conditions
Hypertension, Mineralocorticoid Excess
Interventions
Eplerenone, Amlodipine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
17 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 28, 2026, 5:12 PM EDT
Completed Phase 4 Interventional

Caduet in an Untreated Subject Population

NCT00332761
View directory record Official record
Conditions
Hypertension, Dyslipidemia
Interventions
Caduet
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
34
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Garden Grove, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 28, 2026, 5:12 PM EDT
Completed Phase 3 Interventional Results available

Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension

NCT00281580
View directory record Official record
Conditions
Hypertension
Interventions
Amlodipine 5 mg, Placebo, Telmisartan 20 mg, Telmisartan 40 mg, Amlodipine 10 mg, Telmisartan 80 mg, Amlodipine 2.5 mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
101
States / cities
Fairhope, Alabama • Huntsville, Alabama • Chandler, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Sep 28, 2026, 5:12 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome

NCT00417170
View directory record Official record
Conditions
High Blood Pressure, Metabolic Syndrome, Insulin Resistance, Endothelial Dysfunction
Interventions
Aliskiren, Amlodipine, Placebo Aliskiren, Placebo Amlodipine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Sep 28, 2026, 5:12 PM EDT
Completed Phase 3 Interventional Results available

An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure

NCT00402103
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Amlodipine, Hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 9, 2011 · Synced Sep 28, 2026, 5:12 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension

NCT00591266
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan Medoxomil and amlodipine, Amlodipine
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
50
States / cities
Mesa, Arizona • Phoenix, Arizona • Anaheim, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2011 · Synced Sep 28, 2026, 5:12 PM EDT
Completed Phase 4 Interventional Results available

A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure

NCT00791258
View directory record Official record
Conditions
Hypertension
Interventions
amlodipine and olmesartan medoxomil tablets, hydrochlorothiazide tablets
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
72
States / cities
Birmingham, Alabama • Green Valley, Arizona • Mesa, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 28, 2026, 5:12 PM EDT
Recruiting Not applicable Interventional

Arterial Stiffness and Blood Pressure

NCT06495710
View directory record Official record
Conditions
Hypertension, Vascular Stiffness, Aging
Interventions
Blood pressure treatment algorithm
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Birmingham, Alabama • Nashville, Tennessee • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 28, 2026, 5:12 PM EDT
Completed Phase 4 Interventional

Effects of Amlodipine/Benazepril in the Hypertensive African-American Population With Type 2 Diabetes Mellitus

NCT00367978
View directory record Official record
Conditions
Hypertension
Interventions
Amlodipine/benazepril
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 80 Years
Enrollment
275 participants
Timeline
2001 – 2003
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Sep 28, 2026, 5:12 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension

NCT03640312
View directory record Official record
Conditions
Hypertension
Interventions
QUARTET LDQT, Candesartan
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Bloomingdale, Illinois • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 2, 2025 · Synced Sep 28, 2026, 5:12 PM EDT
Terminated Phase 3 Interventional Results available

Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes

NCT02850081
View directory record Official record
Conditions
Carotid Artery Stenosis, Strokes
Interventions
Statin, Atorvastatin, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
7
States / cities
Ridgewood, New Jersey • Albany, New York • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 28, 2026, 5:12 PM EDT
Completed Phase 3 Interventional

One Year Study to Evaluate the Safety of the Combination of Valsartan and Amlodipine in Patients With Hypertension

NCT00409851
View directory record Official record
Conditions
Hypertension
Interventions
valsartan+amlodipine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Sep 28, 2026, 5:12 PM EDT
Completed Phase 4 Interventional Results available

Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients

NCT00744237
View directory record Official record
Conditions
Hypertension, Type 2 Diabetes Mellitus
Interventions
Nebivolol, Metoprolol ER, HCTZ
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 85 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
62
States / cities
Athens, Alabama • Huntsville, Alabama • Bell Gardens, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2011 · Synced Sep 28, 2026, 5:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Amlodipine Tablets Under Fed Conditions

NCT00601302
View directory record Official record
Conditions
Hypertension, Chronic Stable Angina, Vasospastic Angina
Interventions
Amlodipine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 28, 2026, 5:12 PM EDT
Withdrawn Phase 4 Interventional

Mechanism of Hypertension Treatments in Liver Transplant Recipients (BLOCK LTR-HTN)

NCT05275907
View directory record Official record
Conditions
High Blood Pressure, Liver Transplant, Renal Function Abnormal
Interventions
Amlodipine Besylate, Chlorthalidone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Sep 28, 2026, 5:12 PM EDT